Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Robotic Partial Nephrectomy Outcomes Evaluated

BJU Int; ePub 2017 Dec 12; Xia, Pulido, et al

People with renal cell carcinoma (RCC) who undergo robot-assisted partial nephrectomy (RAPN) at higher volume hospitals appear to experience better perioperative outcomes and have lower rates of positive surgical margin, according to a study involving nearly 19,000 individuals. Participants with RCC underwent RAPN between 2010 and 2013. Investigators grouped cases into very low-, low-, medium-, high-, and very high-volume categories, and evaluated certain outcomes. Among the results:

  • There were no significant differences in 30- and 90-day mortality rates across groups.
  • Patients at very high-volume centers were 53% less likely to experience open conversion than those at very low-volume centers.
  • Patients at high-, medium-, and low-volume centers were also less likely to experience conversion (43%, 40%, and 12%, respectively)
  • Those at very high-, high-, medium-, and low-volume centers were less likely to experience prolonged length of stay (55%, 38%, 25%, and 7%, respectively).
  • They were also less likely to experience positive surgical margin (66%, 41%, 24%, and 24%, respectively).

Citation:

Xia L, Pulido J, Chelluri R, et al. Hospital volume and outcomes of robot-assisted partial nephrectomy. [Published online ahead of print December 12, 2017]. BJU Int. doi:10.1111/bju.14099

This Week's Must Reads

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018

Must Reads in Renal Cell Carcinoma

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018